Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.39 |
| ▸ | CDK2 | P24941 | 7/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786050 | 0.87 | KDR (0.45) | MEN1KMT2ACCNA2CDK2HSP90AA1 | |
| SCHEMBL30675356 | 0.87 | MAPK1 (0.41) | MEN1KMT2ACCNA2CDK2KDR | |
| SCHEMBL741949 | 0.81 | CCNA2 (0.53) | CCNA2CDK2KDRPDGFRB | |
| SCHEMBL8207690 | 0.78 | HSP90AA1 (0.43) | KMT2AHSP90AA1HSP90B1PDGFRB | |
| SCHEMBL19505047 | 0.77 | FGFR4 (0.41) | MEN1KMT2ACCNA2CDK2KDR | |
| SCHEMBL15530492 | 0.76 | HSP90AB1 (0.47) | MEN1KMT2AHSP90AA1KDRHSP90B1 | |
| SCHEMBL21591611 | 0.76 | HSP90AA1 (0.44) | KMT2AHSP90AA1HSP90B1PDGFRB | |
| SCHEMBL28415218 | 0.76 | HSP90AA1 (0.39) | KMT2AHSP90AA1HSP90B1PDGFRB | |
| SCHEMBL15880939 | 0.76 | MEN1 (0.38) | MEN1KMT2ACCNA2CDK2PIM1 | |
| SCHEMBL19553456 | 0.76 | FGFR4 (0.46) | MEN1KMT2ACCNA2CDK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107250135-B | Long-acting dipeptidyl peptidase-IV inhibitor, application and preparation method of intermediate thereof | 四川科伦博泰生物医药股份有限公司 | 2020-05-26 | — | — | CN | claimed |
| CN-107250135-B | Long-acting dipeptidyl peptidase-IV inhibitor, application and preparation method of intermediate thereof | 四川科伦博泰生物医药股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1888066-B1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7906649-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | MEN1 531/4885KMT2A 3061/4885CCNA2 943/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885CCNA2 1469/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885CCNA2 1469/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885CCNA2 1469/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | MEN1 507/4885KMT2A 3179/4885CCNA2 1657/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885KMT2A 3485/4885CCNA2 1469/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | MEN1 1094/4885KMT2A 1453/4885CCNA2 1975/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | MEN1 602/4885KMT2A 3461/4885CCNA2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.